Sanofi Cash Flow Conversion Efficiency
Sanofi cash flow conversion efficiency. Based on the latest financial reports, Sanofi (SNYN) has a cash flow conversion efficiency ratio of 0.043x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.96 Billion ≈ $170.35 Million USD) by net assets (MX$69.57 Billion ≈ $4.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sanofi (2013–2025)
Cash flow conversion efficiency of Sanofi from 2013 to 2025. This chart illustrates how Sanofi's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SNYN share price today for real-time trading data and today's change.
Sanofi Cash Flow Conversion Ratio Explained
Sanofi cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sanofi Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi ranked by their cash flow conversion efficiency. Also see Sanofi stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Safran SA
PA:SAF
|
0.200x |
|
Bank of Nova Scotia
TO:BNS
|
0.148x |
|
Siemens Energy AG
XETRA:ENR
|
0.218x |
|
HITACHI LTD ADR/10
F:HIAA
|
N/A |
|
Western Digital Corporation
NASDAQ:WDC
|
0.124x |
|
PDD Holdings Inc.
NASDAQ:PDD
|
0.110x |
|
Newmont Corporation
AU:NEM
|
0.108x |
|
Banco Bilbao Vizcaya Argentaria SA
MC:BBVA
|
0.278x |
Annual Cash Flow Conversion Efficiency for Sanofi (2013–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi from 2013 to 2025. Review Sanofi free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$71.71 Billion ≈ $4.13 Billion |
MX$10.75 Billion ≈ $618.67 Million |
0.150x | +28.53% |
| 2024-12-31 | MX$77.86 Billion ≈ $4.48 Billion |
MX$9.08 Billion ≈ $522.61 Million |
0.117x | -15.46% |
| 2023-12-31 | MX$74.35 Billion ≈ $4.28 Billion |
MX$10.26 Billion ≈ $590.35 Million |
0.138x | -3.65% |
| 2022-12-31 | MX$73.51 Billion ≈ $4.23 Billion |
MX$10.53 Billion ≈ $605.77 Million |
0.143x | -6.06% |
| 2021-12-31 | MX$69.03 Billion ≈ $3.97 Billion |
MX$10.52 Billion ≈ $605.54 Million |
0.152x | +29.75% |
| 2020-12-31 | MX$63.15 Billion ≈ $3.63 Billion |
MX$7.42 Billion ≈ $426.91 Million |
0.117x | -10.00% |
| 2019-12-31 | MX$59.11 Billion ≈ $3.40 Billion |
MX$7.71 Billion ≈ $444.00 Million |
0.131x | +38.91% |
| 2018-12-31 | MX$59.03 Billion ≈ $3.40 Billion |
MX$5.55 Billion ≈ $319.23 Million |
0.094x | -25.82% |
| 2017-12-31 | MX$58.26 Billion ≈ $3.35 Billion |
MX$7.38 Billion ≈ $424.66 Million |
0.127x | -6.72% |
| 2016-12-31 | MX$57.72 Billion ≈ $3.32 Billion |
MX$7.84 Billion ≈ $451.08 Million |
0.136x | -11.39% |
| 2015-12-31 | MX$58.21 Billion ≈ $3.35 Billion |
MX$8.92 Billion ≈ $513.35 Million |
0.153x | +12.12% |
| 2014-12-31 | MX$56.27 Billion ≈ $3.24 Billion |
MX$7.69 Billion ≈ $442.56 Million |
0.137x | +12.09% |
| 2013-12-31 | MX$57.03 Billion ≈ $3.28 Billion |
MX$6.95 Billion ≈ $400.20 Million |
0.122x | -- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more